Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-026 for Gout
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • 225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • LIFE Offering
    • SEDAR+
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News
Jan 17, 2025 5:00pm EST

XORTX Announces Change of Auditor

Jan 06, 2025 7:00am EST

XORTX Adds Late Stage Gout Program to Pipeline

  • arrow_back
  • 1
  • 2
rss_feed News RSS
©2025 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap